PDCD1 and non-small cell lung carcinoma: As observed previously in patients with non-small cell lung cancer (NSCLC) [36], patients with heterozygous or homozygous variation of GZMB c.128C > A have significantly worse PFS and OS after anti-PD-1 monotherapy in univariable analysis.